This is a working overview of synthetic peptide, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-01-21 and is reviewed periodically as new material appears.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
David Nuttall. Deputy Director, Neurodiversity, Disability and Learning Disability, Department of Health and Social Care. For services to People with Down Syndrome. Hannah Louise O'Callaghan. Co-Founder, Love Grace. For services to Charitable Fundraising and Tackling Violence Against Women. Kathleen Margaret O'Hare. Board Member, Belfast Metropolitan College and Member, Northern Ireland Council for the Curriculum. For services to Education in Northern Ireland. Dr. Tunde Okewale, MBE. Barrister. For services to Criminal Justice and Social Mobility. Dr. Sandra Ngozi Okoro. Lately Senior Vice President and General Counsel, World Bank. For services to Diversity in International Finance. Dr. Robert Leslie Orford. Chief Scientific Advisor for Health, Welsh Government. For services to Health Sciences and Evidence in Health Policy. David John O'Sullivan. Chief Optometric Advisor, Welsh Government. For services to Eye Care in Wales. Professor Nicholas Ossei-Gerning. Course Co-Director, Africa PCR Conference. For services to the Field of Interventional Cardiology. Mildred Baer Palley. Philanthropist. For services to the Arts and to Education. Brian Andrew Palmer. Founder and Chief Executive, Tharsus Group Ltd. For services to Manufacturing and Skills. Catherine Jane Parry. Lately Election Agent, Labour Party. For Political and Public Service. Munir Patel. Chief Executive Officer, XRAIL Group. For services to Rail Exports. Sarah Pateman. Community Safety Manager, Stevenage Borough Council. For services to the Victims of Domestic Abuse in Hertfordshire. Dr. Graham Paterson.
Physical properties of the drug (hydrophobicity, pKa, solubility) The drug formulation (immediate release, excipients used, manufacturing methods, modified release – delayed release, extended release, sustained release, etc.) Whether the formulation is administered in a fed or fasted state Gastric emptying rate Circadian differences Interactions with other drugs/foods: Interactions with other drugs (e.g., antacids, alcohol, nicotine) Interactions with other foods (e.g., grapefruit juice, pomello, cranberry juice, brassica vegetables) Transporters: Substrate of efflux transporters (e.g. P-glycoprotein) Health of the gastrointestinal tract Enzyme induction/inhibition by other drugs/foods: Enzyme induction (increased rate of metabolism), e.g., Phenytoin induces CYP1A2, CYP2C9, CYP2C19, and CYP3A4 Enzyme inhibition (decreased rate of metabolism), e.g., grapefruit juice inhibits CYP3A → higher nifedipine concentrations Individual variation in metabolic differences Age: In general, drugs are metabolized more slowly in fetal, neonatal, and geriatric populations Phenotypic differences, enterohepatic circulation, diet, gender Disease state E.g., hepatic insufficiency, poor renal function Each of these factors may vary from patient to patient (inter-individual variation), and indeed in the same patient over time (intra-individual variation). In clinical trials, inter-individual variation is a critical measurement used to assess the bioavailability differences from patient to patient in order to ensure predictable dosing.
=== First half of 20th century === In the 20th century, many cities built or reorganized formal wholesale market systems for food distribution. For example, Osaka's municipal government documents that its Central Wholesale Market opened in November 1931, following licensing and consolidation steps earlier in the century, and that the wholesale system resumed after wartime disruption. At the same time, the role of wholesale markets changed in many countries as retail formats evolved. FAO notes that the characteristics of wholesale markets have changed "considerably over the last century," in part due to urban growth and the rising role of supermarkets, which changed how food distribution needed to work.
=== Notable cases === Dames & Moore v. Regan KindHearts for Charitable Humanitarian Development v. Geithner Genova Pipe v. Lutnick and Noem Learning Resources, Inc. v. Trump, and Trump v. V.O.S. Selections, Inc. Nintendo of America Inc. v. U.S. Department of the Treasury
Sources: en.wikipedia.org
== Education and early career == Barran went to Godolphin and Latymer School. She moved to the University of Manchester to study chemistry, graduating in 1994. She joined the University of Sussex for her graduate studies, working with Harry Kroto and Tony Stace.
==== International Congress of Refrigeration ==== First held in 1908, the International Congress of Refrigeration of the IIR is a flagship event that converges industry and research. Covering all fields of refrigeration, the Congress, which takes place every four years, reunites key international stakeholders and provides perspectives on the future of the industry in line with sustainable development.
=== Mesenchymal stromal cells (MSCs) === MSCs, when transfused immediately within a few hours post-thawing, may show reduced function or show decreased efficacy in treating diseases as compared to those MSCs which are in log phase of cell growth (fresh). As a result, cryopreserved MSCs should be brought back into the log phase of cell growth in in vitro culture before these are administered for clinical trials or experimental therapies. Re-culturing of MSCs will help in recovering from the shock the cells get during freezing and thawing. Various clinical trials on MSCs have failed which used cryopreserved products immediately post-thaw as compared to those clinical trials which used fresh MSCs.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.